Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Holding TGTX?
Track your performance easily
TGTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.46 - $25.70
Previous Close$23.73
Volume5.15M
Average Volume (3M)3.12M
Market Cap
$3.85B
Enterprise Value$3.57B
Total Cash (Recent Filing)$217.25M
Total Debt (Recent Filing)$112.54M
Price to Earnings (P/E)39.5
Beta3.08
Next Earnings
Nov 12, 2024EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.60
Shares Outstanding154,823,137
10 Day Avg. Volume3,611,700
30 Day Avg. Volume3,117,144
Standard Deviation0.27
R-Squared0.18
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)21.64
Price to Sales (P/S)10.60
Price to Cash Flow (P/CF)165.90
P/FCF Ratio165.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.29
Enterprise Value/Gross Profit16.26
Enterprise Value/Ebitda28.62
Forecast
1Y Price Target
$35.20Price Target Upside41.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
TG Therapeutics News
Bulls Say, Bears Say
Bulls Say
Contract WinTGTX's recent national contract win with the Department of Veterans Affairs (VA) listing Briumvi as the preferred RMS anti-CD20 agent on the VA National Formulary.
Market ShareBriumvi's expanding market share, up to 10% based on new prescription volume trends.
Strategic InvestmentsIncreasing strategic investments to further enhance long-term competitiveness of TGTX's MS franchise.
Bears Say
Competitive RiskThe convenience of sub q Ocrevus is seen as a direct competitive risk to Briumvi, particularly regarding new patient starts.
Earnings1Q24 EPS came in lower than estimates, primarily due to higher R&D expenses.
Growth RateSlowing growth rate in new scripts per quarter while total active centers/providers increasing means that scripts per provider is decreasing.
---
Ownership Overview
31.91% Insiders
17.73% Mutual Funds
30.56% Other Institutional Investors
19.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $6.46 and its highest was $25.70 in the past 12 months.
What is TG Therapeutics’s market cap?
Currently, no data Available
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 54 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Aug 06, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.046 by $0.086.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is $0.02.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 154,823,140 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.046. Following the earnings report the stock price went up 19.582%.
Which hedge fund is a major shareholder of TG Therapeutics?
Among the largest hedge funds holding TG Therapeutics’s share is Woodline Partners LP. It holds TG Therapeutics’s shares valued at 25M.
---
TG Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.20 (41.42% Upside)
$35.20 (41.42% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 97%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 246.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $432.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.25%
12-Months-Change
Fundamentals
Return on Equity
87.78%
Trailing 12-Months
Asset Growth
81.66%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
---
TGTX Earnings Call
Q2 2024
0:00 / 0:00
---
TGTX Stock 12 Month Forecast
Average Price Target
$35.20
▲(41.42% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Aurinia Pharmaceuticals
―
Kura Oncology
―
Karyopharm Therapeutics
―
Best Analysts Covering TGTX
1 Year
1 Year Success Rate
19/26 ratings generated profit
1 Year Average Return
+69.56%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +69.56% per trade.
---